Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter G Rose

Showing results (81-90 of 201) with videos related to

Pageof 21
Sort By:
Gynecologic Oncology|September 9, 2006
Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology GroupPeter G Rose, Benjamin E Greer, Ira R Horowitz, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 13, 2017
Efficacy of Pegylated Liposomal Doxorubicin in Low-Grade Serous Ovarian CarcinomaPeter G Rose, Milena Radeva, Chad M Michener, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group studyLari Wenzel, Helen Q Huang, Bradley J Monk, et al.
Gynecologic Oncology|December 31, 2002
Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinomaPeter G Rose, Kim Mossbruger, Nancy Fusco, et al.
Cancer|March 15, 2008
Surgical versus radiographic determination of para-aortic lymph node metastases before chemoradiation for locally advanced cervical carcinoma: a Gynecologic Oncology Group StudyMichael A Gold, Chunqiao Tian, Charles W Whitney, et al.
Gynecologic Oncology|February 26, 2010
Impact of hydronephrosis on outcome of stage IIIB cervical cancer patients with disease limited to the pelvis, treated with radiation and concurrent chemotherapy: a Gynecologic Oncology Group studyPeter G Rose, Shamshad Ali, Charles W Whitney, et al.
Gynecologic Oncology|April 20, 2019
Time to surgery and its impact on survival in patients with endometrial cancer: A National cancer database studyMariam M AlHilli, Paul Elson, Lisa Rybicki, et al.
Gynecologic Oncology|February 10, 2004
Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) StudyKatherine Y Look, Alan Sandler, John A Blessing, et al.
Gynecologic Oncology|December 9, 2014
A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA)Fiona Simpkins, Richard Drake, Pedro F Escobar, et al.
Gynecologic Oncology|November 9, 2010
An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancerPeter G Rose, Bradley J Monk, Diane Provencher, et al.
Pageof 21

Showing results (81-90 of 201) with videos related to

Sort By:
Pageof 21
Gynecologic Oncology|September 9, 2006
Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology GroupPeter G Rose, Benjamin E Greer, Ira R Horowitz, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 13, 2017
Efficacy of Pegylated Liposomal Doxorubicin in Low-Grade Serous Ovarian CarcinomaPeter G Rose, Milena Radeva, Chad M Michener, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group studyLari Wenzel, Helen Q Huang, Bradley J Monk, et al.
Gynecologic Oncology|December 31, 2002
Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinomaPeter G Rose, Kim Mossbruger, Nancy Fusco, et al.
Cancer|March 15, 2008
Surgical versus radiographic determination of para-aortic lymph node metastases before chemoradiation for locally advanced cervical carcinoma: a Gynecologic Oncology Group StudyMichael A Gold, Chunqiao Tian, Charles W Whitney, et al.
Gynecologic Oncology|February 26, 2010
Impact of hydronephrosis on outcome of stage IIIB cervical cancer patients with disease limited to the pelvis, treated with radiation and concurrent chemotherapy: a Gynecologic Oncology Group studyPeter G Rose, Shamshad Ali, Charles W Whitney, et al.
Gynecologic Oncology|April 20, 2019
Time to surgery and its impact on survival in patients with endometrial cancer: A National cancer database studyMariam M AlHilli, Paul Elson, Lisa Rybicki, et al.
Gynecologic Oncology|February 10, 2004
Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) StudyKatherine Y Look, Alan Sandler, John A Blessing, et al.
Gynecologic Oncology|December 9, 2014
A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA)Fiona Simpkins, Richard Drake, Pedro F Escobar, et al.
Gynecologic Oncology|November 9, 2010
An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancerPeter G Rose, Bradley J Monk, Diane Provencher, et al.
Pageof 21